Swedish Orphan Biovitrum Returns Long-Acting Blood Clotting Factors To Biogen
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec gains sole development and manufacturing rights to long-acting Factor VIII and Factor IX products previously in joint development with Swedish Orphan Biovitrum.